Polatuzumab Vedotin–Based Regimen Improves Overall Survival in Refractory DLBCL

In the POLARGO trial, combining the antibody-drug conjugate polatuzumab vedotin-piiq with rituximab, gemcitabine, and oxaliplatin significantly enhanced survival rates for patients with transplant-ineligible, relapsed or refractory diffuse large B-cell lymphoma (DLBCL). Presented by Dr. Matthew J. Matasar at the EHA 2025 Congress, results indicated a 40% reduction in deaths and increased median overall survival from 12.5 months to 19.5 months. Despite increased toxicity, this regimen showed promising response rates, making it a valuable option for treatment.